Company intelligence / Profile preview

Cairn Diagnostics

Brentwood, Tennessee, United Statescairndiagnostics.com ↗

Ownership: Private
Development stage: Commercial

Overview

Cairn Diagnostics has developed and commercialized the FDA-approved 13C-Spirulina Gastric Emptying Breath Test (GEBT), a non-invasive, non-radioactive diagnostic for gastroparesis. The GEBT is validated against gastric scintigraphy and can be administered in clinical settings or at home via telehealth. Clinical studies reported no deaths or serious adverse events; some participants experienced mild discomfort. The test is covered by Medicare and recommended by the American College of Gastroenterology.

Therapeutic areas: Gastroenterology
Modalities: DeviceNon-pharmacological therapyDiagnostic test
Industry: Metabolite Diagnostics

Drug pipeline

1 asset

Spirulina Gastric Emptying Breath Test

Commercial

Indications: Gastroparesis

Beyond the preview

Go deeper on Cairn Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cairn Diagnostics.

Explore the full profile